- Home
- ADCT
ADCT
ADC Therapeutics SA
as 07-26-2024 4:00pm EST
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
| Founded: | N/A | Country: | Switzerland |
| Employees: | N/A | City: | EPALINGES |
| Market Cap: | 336.8M | IPO Year: | 2020 |
| Target Price: | $8.00 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.36 - $6.04 | Next Earning Date: | 08-06-2024 |
| Revenue: | $68,619,000 | Revenue Growth: | -62.38% |
| Revenue Growth (this year): | 14.11% | Revenue Growth (next year): | 16.34% |
Stock Insider Trading Activity of ADC Therapeutics SA (ADCT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | ADCT | 10% Owner | Jul 1 '24 | Buy | $2.81 | 400,000 | $1,124,000.00 | 12,995,040 | SEC Form 4 |
| Redmile Group, LLC | ADCT | 10% Owner | Jul 1 '24 | Buy | $2.81 | 400,000 | $1,124,000.00 | 15,669,217 | SEC Form 4 |
| Sandor Victor | ADCT | Director | Jun 17 '24 | Sell | $2.89 | 6,995 | $20,215.55 | 80,886 | SEC Form 4 |
| Squarer Ron | ADCT | Director | Jun 17 '24 | Sell | $2.89 | 6,995 | $20,215.55 | 80,663 | SEC Form 4 |
| Pfisterer Thomas | ADCT | Director | Jun 17 '24 | Sell | $2.89 | 1,437 | $4,152.93 | 213,900 | SEC Form 4 |
| BIZZARI JEAN-PIERRE | ADCT | Director | Jun 17 '24 | Sell | $2.89 | 6,995 | $20,215.55 | 79,502 | SEC Form 4 |
| Azelby Robert | ADCT | Director | Jun 17 '24 | Sell | $2.89 | 6,995 | $20,215.55 | 53,005 | SEC Form 4 |
| MALLIK AMEET | ADCT | Chief Executive Officer | May 7 '24 | Sell | $4.48 | 29,731 | $133,194.88 | 1,167,348 | SEC Form 4 |
Latest ADC Therapeutics SA News
ADCT Breaking Stock News: Dive into ADCT Ticker-Specific Updates for Smart Investing
GlobeNewswire
19 days ago
Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development
GlobeNewswire
25 days ago
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Simply Wall St.
a month ago
ADC Therapeutics SA (NYSE:ADCT) Shares Could Be 50% Below Their Intrinsic Value Estimate
MT Newswires
a month ago
ADC Therapeutics to Join Russell 3000 Index
GlobeNewswire
a month ago
ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
GlobeNewswire
2 months ago
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
MT Newswires
2 months ago
Cantor Fitzgerald Initiates ADC Therapeutics at Overweight Rating
GlobeNewswire
2 months ago
ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference
Compare ADCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADCT ADC Therapeutics SA - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.